Protease inhibitor: HIV-1 protease. Inhibits SARS-CoV in silico, binds strongly to key SARS-CoV-2 protease, 3CLpro. Nutho et al. Biochemistry, Apr 15 2020, https://dx.doi.org/10.1021%2Facs.biochem.0c00160; Muralidharan et al. J. Biomol. Struct. Dyn., Apr 16 2020, https://doi.org/10.1080/07391102.2020.1752802; Guy et al. Science, 368 829-830 May 22 2020, https://doi.org/10.1126/science.abb9332.
Biochemicals & reagents
1) Lea and Faulds (2018) Ritonavir; Drugs 52 541 2) Koudriakova et al. (1998) Metabolism of the Human Immunodeficiency Virus Protease Inhibitors Indinavir and Ritonavir by Human Intestinal Microsomes and Expressed Cytochrome P4503A4/3A5: Mechanism-Based Inactivation of Cytochrome P3503A by Ritonavir; Drug Metab. Dispos. 26 552 3) Rock et al. (2014) Characterization of Ritonavir-Mediated Inactivation of Cytochrome P450 3A4; Mol. Pharmacol. 86 665
Ritonavir is a clinically relevant HIV-1/HIV-2 protease inhibitor (2) and a potent inhibitor of cytochrome P450 3A4 (2,3).